MoonLake Immunotherapeutics (MLTX) Interest Expenses (2021 - 2026)

MoonLake Immunotherapeutics' Interest Expenses history runs 6 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 525.0% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a 384.26% increase from a year earlier, with the FY2025 full-year figure at $7.2 million, down 70.93% from the prior year.
• Interest Expenses advanced to $2.3 million in Q1 2026 per MLTX's latest filing, from -$241000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $25.6 million in Q2 2025 and bottomed at -$241000.0 in Q4 2025.
• The 5-year median for Interest Expenses is $207064.0 (2024), against an average of $2.1 million.
• Biggest YoY gain for Interest Expenses was 12265.74% in 2025; the steepest drop was 193.92% in 2025.
• Year by year, Interest Expenses stood at $33757.0 in 2022, then surged by 412.32% to $172945.0 in 2023, then soared by 48.38% to $256612.0 in 2024, then tumbled by 193.92% to -$241000.0 in 2025, then surged by 1054.36% to $2.3 million in 2026.
• Per Business Quant, the three latest MLTX Interest Expenses figures stand at $2.3 million (Q1 2026), -$241000.0 (Q4 2025), and $3.2 million (Q3 2025).